Pancreatic Serous Cystadenocarcinoma
NCI Definition: A metastasizing, slow-growing malignant epithelial neoplasm that arises from the exocrine pancreas. It is characterized by the presence of cysts and is composed of glycogen-rich malignant epithelial cells which produce a watery fluid. Signs and symptoms include upper gastrointestinal bleeding, weight loss, jaundice, and abdominal pain. 
There are 2 clinical trials for pancreatic serous cystadenocarcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain pancreatic serous cystadenocarcinoma as an inclusion criterion, 2 are phase 2 (2 open).
Ipilimumab, nilotinib, and nivolumab are the most common interventions in pancreatic serous cystadenocarcinoma clinical trials.
Significant Genes in Pancreatic Serous Cystadenocarcinoma
CD274 is an inclusion eligibility criterion in 1 clinical trial for pancreatic serous cystadenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and pancreatic serous cystadenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.